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Abstract
Gastrointestinal bleeding (GIB) can occur in patients after left ventricular assist
device (LVAD) implantation. In cases of recurrent GIB, the management of
anticoagulation treatment represents a challenging situation in which the risk of
bleeding recurrence and the need for long-term anticoagulation must be balanced.
This case series describes the successful management of anticoagulation in three
patients with recurrent GIB using fondaparinux.
To our knowledge, these are the first reported cases of recurrent GIB in which a
single dose of subcutaneous fondaparinux was used instead of oral
anticoagulation. None of the patients presented with signs of pump thrombosis or
arterial embolism.
If confirmed by larger studies, the substitution of oral anticoagulation with
subcutaneous, single-dose fondaparinux could represent a safe alternative
treatment in a select group of patients with recurrent GIB.
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Background
Gastrointestinal bleeding (GIB) is a major complication after continuous-flow left
ventricular assist device (LVAD) implantation. Despite the technological innovations
of more recent devices, GIB still occurs in almost 25% of patients.1 Its multifactorial
etiology includes anticoagulation therapy, development of vascular malformations
from an LVAD’s continuous flow function, and acquired Von Willebrand factor
deficiency. In about 30% of cases, the location of the bleeding is not diagnosed, and
the GIB is attributed to vascular malformations at the level of the ileum and jejunum.2
It has been reported that after a GIB episode, about 40% of patients with an LVAD
experience relapsing episodes (recurrent GIB).3 In this subset of patients,
management of the anticoagulation treatment represents a challenge for the
clinician, who must balance the risk of recurrent GIB and the need for long-term
anticoagulation. We describe the successful management of anticoagulation in
three patients with refractory GIB using fondaparinux.
Fondaparinux can be administered via subcutaneous or intravenous routes. The
bioavailability is 100% after subcutaneous administration, and the mean maximum
plasma concentration is achieved at 1.7 h. The long half-life of 17.2 h allows for
once-daily dosing.4 When compared to low molecular weight heparins, fondaparinux
sodium has no effect on fibrinolytic activity or bleeding time, thereby promoting
hemostasis with a favorable bleeding risk profile. Fondaparinux does not bind to or
interact with other plasma proteins or cellular elements, such as platelets or platelet
factor 4; therefore, it does not cause heparin-induced, thrombocytopenia-like
syndrome.5
Institutional Experience
At our institution, 82 patients underwent surgical intervention for advanced heart
failure from 2009 to 2021. Of these 82 patients, 71 underwent LVAD implantation
(51% as a bridge to transplantation with a mean follow-up of 2 years), and 11
patients underwent biventricular VAD implantation (all of them as a bridge to
transplantation). Our anticoagulation protocol is based on the type of device
implanted and the presence of concomitant atrial fibrillation (AF). Patients with a
Jarvik 2000 (Jarvik Heart, Inc., New York, NY) are discharged with warfarin only
(International Normalized Ratio [INR] target of 1.8-2.2 if AF is not present or 2.0-2.5
with concomitant AF). Patients with a HeartWare VAD (HVAD, Medtronic,
Minneapolis, MN) or a HeartMate3 (Abbott Laboratories, Chicago, IL) are
discharged with warfarin (INR target of 2.0-3.0) and aspirin titrated on an ASPItest.
Of the 71 patients implanted with an LVAD, 12 (17%) experienced GIB. Aspirin
therapy was discontinued, and all patients underwent a colonoscopy and
esophagogastroduodenoscopy (EGD) to treat any identified lesions. Oral
anticoagulation treatment was tailored to achieve INR values between 1.5 and 2.0
in 55% of cases and was discontinued, in favor of enoxaparine 100 IU/kg twice/day,
in the remaining 45%. Oral anticoagulation was resumed when hemoglobin levels
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remained stable for at least one week. Subcutaneous, low-molecular-weight heparin
was administered when the INR was lower than 1.5.
Among patients who experienced GIB, 3 (40%) were affected by relapsing episodes
of bleeding and were effectively treated using fondaparinux.

Case Report
Case One
A 76-year-old male received a Jarvik 2000 LVAD for ischemic cardiomyopathy. The
patient was discharged on the following medical regimen: aspirin (100 mg/day) and
warfarin (5mg/day) with an INR target between 1.8 and 2.2. Three months after
device implantation, the patient was readmitted because of severe anemia that
required blood transfusions. Despite positive fecal occult blood (FOB) tests, the
EGD and colonoscopy were unable to detect the source of bleeding. Antiaggregant
treatment was suspended, and a strict follow-up with weekly control of hemoglobin
(Hb) levels was planned. In the following year, the Hb levels continued to decrease,
and FOB tests were persistently positive. At 1-year post-implantation, the patient
was readmitted. Since the EGD confirmed the absence of bleeding sites, we
assumed that the GIB could be the consequence of a small bowel vascular
malformation. Treatment with octreotide (0.1 mg/three times per day) and
propranolol (40 mg/twice per day) was started to induce splanchnic vascular
constriction and down signaling of the vascular endothelial growth factor pathway.
However, due to the persistent anemia, we suspended oral anticoagulation after 4
months of treatment and started fondaparinux (2.5 mg/day). This treatment was
controlled with anti-X coagulation factor (Xa) activity dosage (targeting levels
between 0.6 and 1.0 IU/ml and eventually modified two years later when the patient
suffered a second transient ischemic attack). During the follow-up, the patient
suffered from 2 episodes of transient ischemic attack for which we safely augmented
fondaparinux to 5 mg/day with an anti-Xa activity of 1.8 U/mL. At the one-year followup, a computed tomography scan showed no signs of pump or outflow thrombosis,
and levels of device consumption remained stable. At four years of follow-up, no
new GIB or pump thrombosis events occurred.
Case Two
A 74-year-old male was implanted with a Jarvik 2000 LVAD for ischemic
cardiomyopathy. Due to the presence of concomitant AF, he was discharged on
warfarin (5mg/day) with an INR goal of 2.0-2.5. In the first year following device
implantation, the patient was readmitted to the hospital three times for severe
anemia and positive FOB tests. Both EGD and colonoscopy were negative for
bleeding, and the attempts at medical treatment with octreotide (0.1 mg/three
times per day), propranolol (40 mg/twice per day), and intermittent suspension of
warfarin failed. Therefore, we decided to withhold warfarin and start treatment with
The VAD Journal: Fondaparinux in the LVAD Population

Page 3 of 7

The VAD Journal: The journal of mechanical assisted circulation and heart failure

fondaparinux (2.5 mg/day), ensuring an anti-Xa assay of 0.6-1.0 U/mL. After this
therapeutic modification, the patient was readmitted two more times. The first
readmission was for anemia caused by iron depletion, and the second one was for
GIB relapse (2 years after device implantation). However, in the two years
following the relapse, the patient remained stable with no signs of pump
thrombosis or anemia.
Case Three
A 64-year-old male was implanted with an HVAD for ischemic cardiomyopathy as a
bridge to heart transplantation. His postoperative course was characterized by a
single episode of melena. The patient was discharged on warfarin (5mg/day; target
INR of 2.0-3.0) and aspirin (100 mg/day). He was readmitted for GIB 11 months
after discharge. EGD and colonoscopy were negative for bleeding. A contrast
computed tomography scan revealed a bleeding focus at the ileum level, and an
attempt at arterial embolization was ineffective. Aspirin and warfarin therapy was
promptly suspended, and treatment with fondaparinux (2.5 mg/day) and octreotide
(0.1 mg/three times a day) was started. During the one-year follow-up appointment,
the fondaparinux dosage was increased to 5 mg/day to reach the target anti-Xa
level. At the 2-year follow-up, the patient showed no signs of hemolysis or VAD
thrombosis.

Discussion
The 2013 International Society for Heart and Lung Transplantation guidelines on
mechanical circulatory support provide several recommendations for the
management of GIB in patients with LVADs.6 These include cessation of
anticoagulant/antiaggregant therapy until bleeding resolves and resumption of
antiplatelet and anticoagulation therapy after resolution of the first episode of GIB.
For recurrent GIB without a source or with a source not amenable to treatment, it is
recommended that the dose, intensity, or even the use of antiplatelet drugs or
warfarin should be re-evaluated.6 The updated 2019 guidelines note that reducing
the LVAD speed to induce pulsatility may decrease GIB risk.7 In this series, all the
patients exhibited well-defined arterial pulsatility at discharge and during GIB
episodes; thus, pump speed levels remained unchanged.
Pharmacological adjunctive therapies aim to induce splanchnic vascular constriction
(octreotide8) and downregulate the vascular endothelial growth factor signaling that
leads to arteriovenous malformations (ACE-Inhibitors,9 beta-blockers,10 and inhaled
desmopressin11). Our institutional policy utilizes such pharmacological treatment
after GIB whenever possible. However, in the case of recurrence of GIB, suspension
of oral anticoagulant treatment is to be considered.
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In this case series, two patients were implanted with the Jarvik 2000, and one patient
received an HVAD. It has been reported that the axial flow, compared to the
centrifugal flow, is responsible for greater shear stress that results in a reduction of
platelet count.12 Thus, patients with Jarvik 2000s may be less affected by device
thrombosis with sub-therapeutic INR levels or after suspension of aspirin when
compared to patients with the HVAD that was associated with a hypercoagulable
state.12 Given the limited number of patients, no decisive conclusions can be drawn.
The management of anticoagulation in patients with LVADs and recurrent GIB
requires a balance between the thromboembolic and hemorrhagic risks. Different
anticoagulation protocols have been proposed, including the use of enoxaparin13
and dabigatran.14 However, a randomized controlled trial showed an excess of
thromboembolic events in dabigatran-treated patients when compared to antivitamin K-treated patients.15 Fondaparinux has been used in patients with LVADs
with heparin-induced thrombocytopenia;16 it is rapidly and completely absorbed after
subcutaneous administration and is distributed mainly in the blood. Furthermore,
fondaparinux’s activity can be monitored with an anti-Xa assay. A meta-analysis of
seven studies (mainly enrolling patients affected by acute myocardial infarction)
compared enoxaparin with fondaparinux and showed similar rates of mortality and
major cardiovascular complications.17 However, at the midterm follow-up, major,
minor and total bleeding were significantly lower with fondaparinux when compared
to enoxaparin (OR: 0.50, 95% CI: 0.28–0.89; P = 0.02, OR: 0.51, 95% CI: 0.31–0.84;
P = 0.009 and OR: 0.48, 95% CI: 0.34–0.69; P = 0.0001, respectively).17 This finding
may explain why fondaparinux proved to be effective in our patients, where the
selective action on factor X and the lower impact on other coagulation components
may have prevented the recurrence of gastrointestinal hemorrhage.
To our knowledge, these are the first reported cases of long-term follow-up of
recurrent GIB managed by withholding oral anticoagulation and administering a
single dose of subcutaneous fondaparinux, with a target anti-Xa activity range of
0.6-1.0 U/mL. Only Patient 2 presented with relapses of anemization after initiation
of fondaparinux treatment with the first relapse correlated to iron deficiency. None
of the patients presented with signs of pump thrombosis.

Conclusion
Based on our experience, the substitution of oral anticoagulation with
subcutaneous single-dose fondaparinux could be an alternative treatment in a
select group of patients with recurrent GIB, where no clinical foci of bleeding are
found and other medical options have failed.
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In these high-risk patients, it is mandatory to monitor kidney function and routinely
test the efficacy of this innovative approach by evaluating anti-Xa activity levels in
order to titrate the drug dose and prevent possible side effects.
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